Sep 09, 2025
Volition Signs First Human Out Licensing Deal
Aug 14, 2025
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
May 19, 2025
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
May 07, 2025
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
Apr 29, 2025
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
Mar 31, 2025
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Mar 27, 2025
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
Mar 26, 2025
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Mar 21, 2025
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Mar 20, 2025
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
Mar 17, 2025
Volition Proudly Sponsors the 44th ISICEM Congress
Mar 13, 2025
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Mar 11, 2025
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Mar 04, 2025
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Feb 06, 2025
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Feb 05, 2025
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
Jan 30, 2025
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
Jan 08, 2025
Volition Issues Business Review 2024
Dec 12, 2024
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Dec 10, 2024
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening